Airain Ltd’s Intellia Therapeutics NTLA Stock Holding History

Airain Ltd’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$449K	Buy	28,077 +1,027	+4%	+$14.3K	0.02%	562
2017 Q1	$381K	Buy	+27,050	New	+$363K	0.02%	562

Other funds holding NTLA

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Airain Ltd's NTLA Position: Q2 2017 in Review

Airain Ltd increased its Intellia Therapeutics (NTLA) stake by 3.8% in Q2 2017, buying an estimated $14.3K and bringing the position to 28,077 shares worth $449K. The position accounts for 0.02% of the portfolio, ranked #562.

Airain Ltd first reported a position in NTLA in Q1 2017 and has held it in 2 quarters since. 85 funds tracked by Wall St. Rank hold NTLA as of Q2 2017.

Airain Ltd held 28,077 shares of Intellia Therapeutics worth $449K as of Q2 2017.
Airain Ltd bought 1,027 Intellia Therapeutics shares in Q2 2017, an estimated $14.3K.
Intellia Therapeutics made up 0.02% of Airain Ltd's portfolio in Q2 2017, its #562 holding.
Airain Ltd first reported a position in Intellia Therapeutics in Q1 2017 and has held it in 2 quarters since.
85 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2017.

Based on Airain Ltd's 13F filing for Q2 2017, filed 8 Aug 2017.